Helicobacter Pylori Infections - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Helicobacter Pylori Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Helicobacter Pylori Infections - Pipeline Review, H2 2014', provides an overview of the Helicobacter Pylori Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Helicobacter Pylori Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Helicobacter Pylori Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Helicobacter Pylori Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Helicobacter Pylori Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Helicobacter Pylori Infections Overview 8
Therapeutics Development 9
Pipeline Products for Helicobacter Pylori Infections - Overview 9
Pipeline Products for Helicobacter Pylori Infections - Comparative Analysis 10
Helicobacter Pylori Infections - Therapeutics under Development by Companies 11
Helicobacter Pylori Infections - Therapeutics under Investigation by Universities/Institutes 13
Helicobacter Pylori Infections - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Helicobacter Pylori Infections - Products under Development by Companies 18
Helicobacter Pylori Infections - Products under Investigation by Universities/Institutes 19
Helicobacter Pylori Infections - Companies Involved in Therapeutics Development 20
Sequella, Inc. 20
Daewoong Pharmaceutical Co., Ltd. 21
MerLion Pharmaceuticals Pte Ltd 22
ImmunoBiology Ltd. 23
EpiVax, Inc. 24
Sigmoid Pharma Ltd. 25
Shanghai Zerun Biotechnology Co., Ltd. 26
RedHill Biopharma Ltd. 27
ImevaX 28
Helicobacter Pylori Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(rifabutin + amoxicillin sodium + omeprazole) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SQ-109 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
finafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Subunit Vaccine for Helicobacter Pylori Infections - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Human Liporale-H.pylori Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Antibiotics for Helicobacter Pylori Infections - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
helicobacter pylori vaccine [Hel-305] (multivalent) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
helicobacter pylori vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
HPi-1 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IMX-101 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DWJ-1325 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Nitroimidazole Antibiotics for Infectious Diseases - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Subunit Vaccine for Helicobacter Pylori Infections - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Vaccine for H.pylori Infections - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Helicobacter Pylori Infections - Recent Pipeline Updates 56
Helicobacter Pylori Infections - Dormant Projects 60
Helicobacter Pylori Infections - Product Development Milestones 61
Featured News & Press Releases 61
Dec 23, 2013: RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study 61
Dec 17, 2013: RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection 62
Dec 02, 2013: ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement on Development of Pharmaceutical Formulation for IMX101 63
Oct 30, 2013: RedHill Biopharma Initiates Phase III Study of RHB-105 for H. pylori Infection 63
Oct 22, 2013: RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 Phase III Study - to Commence Shortly 65
Aug 21, 2013: Eisai receives approval to market Pariet triple formulation packs Rabecure® 400 and 800 and Rabefine, for primary and secondary H. Pylori eradication respectively, in Japan 66
Dec 10, 2012: Eisai Receives Six-month Pediatric Exclusivity For Proton-pump Inhibitor Aciphex In US 66
Nov 07, 2012: MerLion Pharma Successfully Completes Phase I Clinical Study With Intravenously Administered Finafloxacin 66
May 31, 2012: Eisai Seeks Approval To Market Pariet Triple Formulation Pack In Japan For Helicobacter Pylori Eradication 67
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products under Development for Helicobacter Pylori Infections, H2 2014 9
Number of Products under Development for Helicobacter Pylori Infections - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Helicobacter Pylori Infections - Pipeline by Sequella, Inc., H2 2014 20
Helicobacter Pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 21
Helicobacter Pylori Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2014 22
Helicobacter Pylori Infections - Pipeline by ImmunoBiology Ltd., H2 2014 23
Helicobacter Pylori Infections - Pipeline by EpiVax, Inc., H2 2014 24
Helicobacter Pylori Infections - Pipeline by Sigmoid Pharma Ltd., H2 2014 25
Helicobacter Pylori Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2014 26
Helicobacter Pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2014 27
Helicobacter Pylori Infections - Pipeline by ImevaX, H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Assessment by Combination Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Helicobacter Pylori Infections Therapeutics - Recent Pipeline Updates, H2 2014 56
Helicobacter Pylori Infections - Dormant Projects, H2 2014 60